DE69623141D1 - Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit Aufmerksamkeitsstörungen - Google Patents
Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit AufmerksamkeitsstörungenInfo
- Publication number
- DE69623141D1 DE69623141D1 DE69623141T DE69623141T DE69623141D1 DE 69623141 D1 DE69623141 D1 DE 69623141D1 DE 69623141 T DE69623141 T DE 69623141T DE 69623141 T DE69623141 T DE 69623141T DE 69623141 D1 DE69623141 D1 DE 69623141D1
- Authority
- DE
- Germany
- Prior art keywords
- tomoxetine
- attention deficit
- treat hyperactivity
- treat
- hyperactivity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/371,341 US5658590A (en) | 1995-01-11 | 1995-01-11 | Treatment of attention-deficit/hyperactivity disorder |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69623141D1 true DE69623141D1 (de) | 2002-10-02 |
DE69623141T2 DE69623141T2 (de) | 2003-04-24 |
Family
ID=23463572
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69623141T Expired - Lifetime DE69623141T2 (de) | 1995-01-11 | 1996-01-09 | Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit Aufmerksamkeitsstörungen |
DE200512000011 Active DE122005000011I2 (de) | 1995-01-11 | 1996-01-09 | Verwendung von Tomoxetin zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsst¦rungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE200512000011 Active DE122005000011I2 (de) | 1995-01-11 | 1996-01-09 | Verwendung von Tomoxetin zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsst¦rungen |
Country Status (28)
Country | Link |
---|---|
US (1) | US5658590A (de) |
EP (1) | EP0721777B1 (de) |
JP (2) | JPH10512262A (de) |
KR (1) | KR19980701276A (de) |
CN (2) | CN1781480A (de) |
AT (1) | ATE222757T1 (de) |
AU (1) | AU688665B2 (de) |
BR (1) | BR9606903A (de) |
CA (1) | CA2209735C (de) |
CZ (1) | CZ292226B6 (de) |
DE (2) | DE69623141T2 (de) |
DK (1) | DK0721777T3 (de) |
ES (1) | ES2181845T3 (de) |
FI (1) | FI119354B (de) |
FR (1) | FR10C0041I2 (de) |
HU (1) | HU227306B1 (de) |
LU (1) | LU91238I2 (de) |
NL (1) | NL300180I2 (de) |
NO (1) | NO317027B1 (de) |
NZ (1) | NZ301500A (de) |
PL (1) | PL187573B1 (de) |
PT (1) | PT721777E (de) |
RO (1) | RO118374B1 (de) |
RU (1) | RU2163802C2 (de) |
SI (1) | SI0721777T1 (de) |
TR (1) | TR199700627T1 (de) |
UA (1) | UA43385C2 (de) |
WO (1) | WO1996021430A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
GB9613243D0 (en) * | 1996-06-25 | 1996-08-28 | Britannia Pharmaceuticals Ltd | Attention deficit hyperactive disorder |
UA57107C2 (uk) * | 1997-09-23 | 2003-06-16 | Елі Ліллі Енд Компані | Спосіб лікування розладу поведінки |
UA56257C2 (uk) * | 1997-09-23 | 2003-05-15 | Елі Ліллі Енд Компані | Спосіб лікування неадекватної визивної поведінки |
CA2304112A1 (en) * | 1997-09-23 | 1999-04-01 | John Harrison Heiligenstein | Treatment of attention-deficit/hyperactivity disorder |
US5902797A (en) * | 1997-11-10 | 1999-05-11 | Beth Israel Deaconess Medical Center | Nutritional supplement for use in the treatment of attention deficit |
AU756373B2 (en) * | 1998-04-09 | 2003-01-09 | Pharmacia & Upjohn Company | New treatments for nervous disorders |
US6586427B2 (en) | 1998-04-09 | 2003-07-01 | Pharmacia & Upjohn Company | Treatments for nervous disorders |
AU761844C (en) * | 1998-11-09 | 2004-09-23 | F. Hoffmann-La Roche Ag | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
US6898455B2 (en) * | 1999-10-29 | 2005-05-24 | The Mclean Hospital Corporation | Method for providing optimal drug dosage |
US6400978B1 (en) | 1999-10-29 | 2002-06-04 | The Mclean Hospital Corporation | Method and apparatus for detecting mental disorders |
DZ3282A1 (fr) * | 2000-03-07 | 2001-09-13 | Lilly Co Eli | Traitement du psoriasis |
US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US20040034106A1 (en) * | 2001-11-06 | 2004-02-19 | Read Holly Ann | Treatment of anxiety disorders |
PL369311A1 (en) * | 2001-12-11 | 2005-04-18 | Eli Lilly And Company | Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure |
ES2315525T3 (es) | 2002-08-23 | 2009-04-01 | Eli Lilly And Company | Derivados de 2-(feniltiometil)-morfolina para uso como inhibidores selectivos de la recaptacion de norepinefrina. |
GB0219687D0 (en) * | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
US8367111B2 (en) | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
WO2004103356A2 (en) * | 2003-05-15 | 2004-12-02 | Eli Lilly And Company | Treatment of emotional dysregulation |
WO2005011583A2 (en) * | 2003-07-28 | 2005-02-10 | Leslie Joe Dunaway | Treatment of allergic rhinitis and asthma |
EP1660064A2 (de) * | 2003-08-27 | 2006-05-31 | Eli Lilly And Company | Behandlung von lernstörungen und motorischen störungen mit norepinephrin-wiederaufnahme-hemmern |
US20060241188A1 (en) * | 2003-08-27 | 2006-10-26 | Elililly And Company | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors |
US20050152974A1 (en) * | 2003-12-31 | 2005-07-14 | Garth Boehm | Atomoxetine formulations |
US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
US20070219201A1 (en) * | 2004-05-27 | 2007-09-20 | Warner-Lambert Company Llc | Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders |
CA2561386A1 (en) * | 2004-06-28 | 2006-01-12 | Teva Pharmaceutical Fine Chemicals S.R.L. | Enantiomerically pure atomoxetine and tomoxetine mandelate |
US7439399B2 (en) * | 2004-06-28 | 2008-10-21 | Teva Pharmaceutical Fine Chemicals | Processes for the preparation of atomoxetine hydrochloride |
CA2568629A1 (en) | 2004-07-22 | 2006-02-23 | Teva Pharmaceutical Fine Chemicals S.R.L. | Polymorphs of atomoxetine hydrochloride |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
NZ589750A (en) | 2004-10-21 | 2012-07-27 | Aptalis Pharmatech Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
WO2006108120A1 (en) * | 2005-04-05 | 2006-10-12 | Teva Pharmaceutical Fine Chemicals S.R.L. | Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
EP1951643A1 (de) * | 2005-11-23 | 2008-08-06 | Auspex Pharmaceuticals Inc. | Substituierte aryloxypropylamine mit serotoninergischer und/oder norepinephrinergischer aktivität |
WO2007065655A1 (en) | 2005-12-07 | 2007-06-14 | Neurosearch Sweden Ab | Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission |
US20080020387A1 (en) * | 2006-03-31 | 2008-01-24 | Lawrence Donald G | Biomarker-optimized adhd treatment |
US20080146675A1 (en) * | 2006-04-05 | 2008-06-19 | Eugenio Castelli | Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability |
US20080031932A1 (en) * | 2006-08-04 | 2008-02-07 | Watson Laboratories, Inc. | Transdermal atomoxetine formulations and associated methods |
US20080145318A1 (en) * | 2006-12-13 | 2008-06-19 | Midha Kamal K | Atomoxetine formulations and associated methods |
WO2008122019A1 (en) * | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
US20100069390A1 (en) * | 2008-09-05 | 2010-03-18 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
RU2395313C2 (ru) * | 2008-10-15 | 2010-07-27 | Татьяна Прохоровна Тетерина | Способ коррекции синдрома дефицита внимания и гиперактивности |
NZ600256A (en) | 2009-12-02 | 2014-05-30 | Aptalis Pharma Ltd | Fexofenadine microcapsules and compositions containing them |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
EP4011364B1 (de) | 2011-03-23 | 2023-12-13 | Ironshore Pharmaceuticals & Development, Inc. | Verfahren und zusammensetzungen zur behandlung von aufmerksamkeitsdefizitsyndrom |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
WO2013119794A1 (en) | 2012-02-08 | 2013-08-15 | Supernus Pharmaceuticals, Inc. | Modified release formulations of viloxazine |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
DK2838510T3 (en) | 2013-11-08 | 2016-12-19 | Lilly Co Eli | Atomoxetine solution |
CA2936740C (en) | 2014-10-31 | 2017-10-10 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5457121A (en) * | 1994-09-02 | 1995-10-10 | Eli Lilly And Company | Cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles as inhibitors of serotonin reuptake |
ZA958725B (en) * | 1994-10-20 | 1997-04-16 | Lilly Co Eli | Treatment of disorders with duloxetine |
-
1995
- 1995-01-11 US US08/371,341 patent/US5658590A/en not_active Expired - Lifetime
-
1996
- 1996-01-04 RO RO97-01260A patent/RO118374B1/ro unknown
- 1996-01-04 NZ NZ301500A patent/NZ301500A/en not_active IP Right Cessation
- 1996-01-04 HU HU9801283A patent/HU227306B1/hu active Protection Beyond IP Right Term
- 1996-01-04 BR BR9606903A patent/BR9606903A/pt unknown
- 1996-01-04 CZ CZ19972145A patent/CZ292226B6/cs not_active IP Right Cessation
- 1996-01-04 JP JP8521732A patent/JPH10512262A/ja not_active Withdrawn
- 1996-01-04 KR KR1019970704665A patent/KR19980701276A/ko not_active Application Discontinuation
- 1996-01-04 AU AU46938/96A patent/AU688665B2/en not_active Expired
- 1996-01-04 WO PCT/US1996/000091 patent/WO1996021430A1/en not_active Application Discontinuation
- 1996-01-04 CN CNA2005100832846A patent/CN1781480A/zh active Pending
- 1996-01-04 RU RU97113060/14A patent/RU2163802C2/ru active
- 1996-01-04 PL PL96321273A patent/PL187573B1/pl unknown
- 1996-01-04 CN CN96191412A patent/CN1168095A/zh active Pending
- 1996-01-04 CA CA002209735A patent/CA2209735C/en not_active Expired - Lifetime
- 1996-01-04 TR TR97/00627T patent/TR199700627T1/xx unknown
- 1996-01-09 DE DE69623141T patent/DE69623141T2/de not_active Expired - Lifetime
- 1996-01-09 DE DE200512000011 patent/DE122005000011I2/de active Active
- 1996-01-09 ES ES96300157T patent/ES2181845T3/es not_active Expired - Lifetime
- 1996-01-09 EP EP96300157A patent/EP0721777B1/de not_active Expired - Lifetime
- 1996-01-09 SI SI9630534T patent/SI0721777T1/xx unknown
- 1996-01-09 AT AT96300157T patent/ATE222757T1/de active
- 1996-01-09 DK DK96300157T patent/DK0721777T3/da active
- 1996-01-09 PT PT96300157T patent/PT721777E/pt unknown
- 1996-04-01 UA UA97073620A patent/UA43385C2/uk unknown
-
1997
- 1997-07-08 NO NO19973170A patent/NO317027B1/no not_active IP Right Cessation
- 1997-07-09 FI FI972922A patent/FI119354B/fi not_active IP Right Cessation
-
2005
- 2005-03-04 NL NL300180C patent/NL300180I2/nl unknown
- 2005-08-10 JP JP2005232408A patent/JP2005325139A/ja active Pending
-
2006
- 2006-05-03 LU LU91238C patent/LU91238I2/fr unknown
-
2010
- 2010-08-20 FR FR10C0041C patent/FR10C0041I2/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69623141T2 (de) | Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit Aufmerksamkeitsstörungen | |
ATE241358T1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
EA199700186A1 (ru) | Новые дипептидные амидины, используемые в качестве ингибиторов тромбина | |
DE69435330D1 (de) | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen | |
DE69403906D1 (de) | Methode zur behandlung von spontan brennbaren katalysatoren | |
ATE159424T1 (de) | Verwendung von hydroxylierte carbonsäure zur behandlung von nägeln | |
EA199800152A1 (ru) | Лечение синдрома дефицита внимания/гиперактивности | |
DE59202663D1 (de) | Verwendung eines UV-Strahlers zur Behandlung von Oberflächen. | |
ATE95694T1 (de) | Verwendung von bezafibrat zur behandlung von diabetes. | |
DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
DE69720064D1 (de) | Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen | |
ATE214923T1 (de) | Verwendung von (r)-verapamil als medizin zur behandlung von angina | |
ATE291920T1 (de) | Verwendung von quetiapin für aufmerksamkeitsmangel-hyperaktivitätsstörungen oder verhaltensstörungen | |
DE59901695D1 (de) | Verfahren zur Herstellung von 2,4-Dichlor-3,5-dimethylfluorbenzol | |
ATE116965T1 (de) | Reinigungsprozess für n,n-diethylmandelsäureamid. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R071 | Expiry of right |
Free format text: PRODUCT NAME: ATOMOXETIN, GEGEBENENFALLS IN FORM EINES SALZES WIE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 60775.00.00 60775.01.00 60775.02.00 60775.03.00 60775.04.00 60775.05.00 20041207 FIRST RL 00006/0379 20040527 EGISTRATION: GROSSBRITANNIEN PL 00006/0374 PL 00006/0375 PL 00006/0376 PL 00006/0377 PL 00006/0378 P Spc suppl protection certif: 122005000011 Filing date: 20050312 Expiry date: 20160110 Extension date: 20190527 |